openPR Logo
Press release

Motif Biosciences Unveil Novel Solutions for the Treatment Deadly Superbugs

09-11-2017 11:34 AM CET | Health & Medicine

Press release from: SMi Group

Superbugs and Superdrugs USA

Superbugs and Superdrugs USA

SMi Group will welcome the expertise of David Huang when he presents exclusive updates on Iclaprim, a novel diaminopyrimidine, for the treatment of serious gram- positive infections, at Superbugs & Superdrugs USA this fall. The talk will explore how Iclaprim addresses an unmet medical need in hospitalized patients with serious and life-threatening infections including MRSA.

With over 15 years of clinical, academic, industry, and research experience in medicine and in the subspecialty of infectious diseases, David Huang is Chief Medical Officer at Motif Biosciences, a clinical stage biopharmaceutical company which specializes in developing novel antibiotics.

He is currently serving as an adjunct Assistant Professor at Rutgers New Jersey Medical School and is well versed in the design, execution and close out of Phase I - III clinical trials for both antibacterial and antiviral agents. His research interests include bacteriology and virology, especially the epidemiology, pathogenesis and treatment of multidrug resistant organisms.
In the run-up to his presentation, SMi Group caught up with David to discuss current industry developments and his upcoming address this November.

From the answers provided, it is apparent that a lack of funding and strict regulatory requirements is still a common pitfall in the fight against AMR.

“I think industry incentives are very important and the biggest challenges (1) adequate government and non-government funding for the entire research and development of antibiotics; (2) strict and long regulatory requirements and timelines for developing and receiving approval for antibiotics for treatment of serious and life threatening infections; (3) awareness and education of the importance of addressing the prevention of selective pressure and in adequate use of antibiotics (animals feeds, improper use by healthcare providers, and use in developing countries without the need of prescriptions, and others); (4) reimbursements for antibiotics; (5) better and faster rapid diagnostics for all types of infections; and (6) increasing the prestige and compensation for microbiologists and infectious diseases care providers.” David Huang, Chief Medical Officer at Motif Biosciences.

The full interview in available to read in the event download center at
http://www.smi-online.co.uk/goto/2017superbugsusa.asp#tab_downloads

Other notable speakers on the agenda will include representatives from: Janssen, BARDA, CARB-X, Pfizer, MedImmune, Visterra, Contrafect, Centauri Therapeutics, UNT Health Science Center , Microbiotix and Merck.

A detailed program and full speaker line-up is available at https://www.smi-online.co.uk/pharmaceuticals/northamerica/superbugs-superdrugs-usa?utm_medium=www.superbugs-usa.com&utm_source=P-226&utm_campaign=openpr

Superbugs & Superdrugs USA will take place on 13th & 14th November at the Renaissance Woodbrigde Hotel in Iselin, New Jersey. Sponsored by Merck and Soligenix.

--- END ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Contact Information:
For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk

Ground & First Floor
1 Westminster Bridge Road
London, SE1 7XW

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Motif Biosciences Unveil Novel Solutions for the Treatment Deadly Superbugs here

News-ID: 707911 • Views: 587

More Releases from SMi Group

Leading Microbiologists to meet at SMi’s 10th Annual Pharmaceutical Microbiolo …
SMi Reports: Leading pharmaceutical microbiologists and industry experts to meet at SMi’s 10th Anniversary Pharmaceutical Microbiology UK Conference taking place in London on 17-18 January 2022. SMi Group announces the 10th Annual Pharmaceutical Microbiology UK Conference to take place on the 17 - 18 January 2022 in London. The 10th Anniversary conference theme is “Exploring Robust Risk-Based Microbiological Control Strategy”. The two-day conference will be chaired by Di Morris, Clinical Auditor,
Keynote address from TÜV SÜD and Amgen at Medical Devices and IVD Conference i …
The MDR and IVDR updates will have a profound impact on the medical device industry, bringing certain products into regulatory scope that were previously excluded, introducing new manufacturing requirements, and increasing the burden for post-market surveillance. What does this mean for the future of the Medical Devices and IVD industry? More information on the programme and speaker line-up can be found here: www.medicaldevices-ivd.com/pr3openpr IVDR implementation: State of
Registration Opens for Energy from Waste Conference 2021
SMi Group’s Energy from Waste conference will return to London for its 14th year this December SMi Group are pleased to announce the return of their Energy from Waste conference, which will return to London for its 14th year on 1st – 2nd December 2021. Due to the current political climate, the Energy From Waste industry is changing dramatically. This years, conference agenda will explore how technological innovations and new policy are
Workshop on Connected Devices and Digital Health: How to Navigate the U.S. FDA U …
SMi Reports: Workshop will include case studies related to emergent digital health innovations currently coming out of Silicon Valley, software apps connected to drug delivery platforms, and new applications for medical software. Our conference co-chair Shannon Clark has conducted numerous workshops on human factors and usability testing throughout the world, from Stockholm to Shanghai. This year’s workshop will discuss the U.S. FDA Human Factors Engineering Process in the context of digital

All 5 Releases


More Releases for Superbugs

Interview with Martin Everett speaker at SMi's Superbugs & Superdrugs Conference
SMi Reports: An Interview with Martin Everett, Chief Scientific Officer, at Antabio, who will be speaking at SMi's highly anticipated 22nd Annual Superbugs & Superdrugs Conference on the 30th and 31st March 2020 in London. This year's global focused two-day conference pharmaceutical is for industry professionals looking to gain an in-depth knowledge of the scientific, economic, and regulatory challenges facing the critical global issue of antibiotic resistance. For interested individuals to attend
Four weeks until SMi’s 21st Annual Superbugs & Superdrugs Conference 2019
SMi Reports: Senior industry experts will gather in London to discuss the recent advances made in combating antibiotic resistance. As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. For this reason, the Superbugs & Superdrugs conference, taking
Registration Officially Opens for the 21st Annual Superbugs & Superdrugs Confere …
As the global threat of antimicrobial resistance continues to grow, the advances of modern medicine are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. SMi’s highly anticipated Superbugs & Superdrugs conference is set to return to London, UK for its 21st year running, on the 18th & 19th March 2019 (http://www.superbugssuperdrugs.com/openpr). This
W. J. Wiess and A.S. Lynch invitation to SMi’s Superbugs & Superdrugs USA Conf …
SMi Group reports: William J. Weiss - University of North Texas Health Science Center and Anthony Simon Lynch - Janssen supporting SMi's Superbugs & Superdrugs USA Conference, which is due to take place this November in New Jersey William and Anthony are chairing SMi's Superbugs & Superdrugs USA Conference and encourage all involved in AMR to join experts from multiple disciplines, in the field of infectious disease representing research, regulatory, funding,
Superbugs & Superdrugs USA Conference returns to New Jersey this November
SMi Group reports: agenda released for 3rd annual Superbugs & Superdrugs USA conference Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group is pleased to announce the release of the official agenda for the 3rd annual Superbugs & Superdrugs USA Conference, which is due to take place in Iselin, New Jersey on November 12 - 13, 2018. Antimicrobial resistance, leading to the
Antibiotic Drug Experts + Senior Industry Leaders set to Gather at Superbugs USA
SMi Group will open doors in 3 weeks to host the next annual USA Superbugs summit when it returns to Iselin, New Jersey on Nov 13th – 14th. http://www.superbugs-usa.com/opr Following over two decades of expertise in Europe, the USA show will gather senior industry experts to delve deeper into core issues surrounding government funding and initiatives, breakthroughs in drug discovery, strategies to strengthen the antibiotic pipeline and resistance prevention. Highlights will include